#HCWB

StockTitan

@stocktitan.net

3 months ago

HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules HCW Biologics (NASDAQ: HCWB) announced a warrant inducement agreement dated Nov 19, 2025 that amends exercise prices and triggers immediate exercises of prior warrants.The investor agreed to a reduced exercise price of $2.66 for November 2024 and May 2025 warrants, resulting in exercises to purchase 167,925 and 1,342,280 shares respectively, with gross proceeds of approximately $4.0 million before fees. In return, HCW will issue 3,020,410 unregistered new warrants exercisable at $2.41, expiring 5.5 years after original issuance.The closing is expected on or about Nov 20, 2025, Maxim Group LLC is financial advisor, and the company has agreed to file a registration statement covering resale of shares underlying the new warrants.

#HCWB HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

3 months ago

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease cytokine that maintains proper numbers and functions of regulatory T cells to control excessive inflammation Gateway to development of a first-in-kind

#HCWB HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

4 months ago

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results HCW Biologics (NASDAQ: HCWB) reported Q3 2025 results and business highlights on Nov 14, 2025. The company expects to dose the first patient in a Phase 1 study of HCW9302 in Q4 2025 and opened two clinical sites for an alopecia areata trial. During Q3 the company issued 475,000 shares for $2.2M under its standby equity purchase agreement.Q3 revenue was $15,606 (Q3 2024: $426,423); nine-month revenue was $27,222 (9M 2024: $2.2M). Q3 net loss was $4.6M; nine-month net loss was $8.7M. Management stated substantial doubt about going concern without additional funding and faces a Nasdaq equity-rule cure deadline of Dec 31, 2025.

#HCWB HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

4 months ago

HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer HCW Biologics (NASDAQ: HCWB) presented updated preclinical data for its tetra-valent, pembrolizumab-based immune checkpoint inhibitor HCW11-040 at SITC2025 (Nov 5–9, 2025).HCW11-040 is a multi-functional fusion protein combining pembrolizumab with IL-15, IL-7 domains and a TGF-β trap. Preclinical results reported: PD-1/PD-L1 blockade equivalent to pembrolizumab, superior expansion/activation of TPEX and memory T cells, enhanced human PBMC anti-tumor activity in organoid models, no evidence of excessive inflammatory responses after subcutaneous dosing, and a streamlined GMP-like manufacturing process.

#HCWB HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

4 months ago

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting HCW Biologics (NASDAQ: HCWB) presented preclinical data for its tetra-valent, TRBC-based T‑Cell Engager (TCE) program at the SITC 40th Annual Meeting (Nov 5–9, 2025) in National Harbor, MD.Key points: the lead candidate HCW11-018b showed tumor shrinkage in xenograft and PDX models, 100% survival in treated tumor-bearing mice versus 0% in untreated controls, activation of exhausted tumor‑infiltrating T cells, favorable tolerability and long serum half-life in non‑human primates, subcutaneous dosing, and a streamlined GMP manufacturing process without Fc fusion.

#HCWB HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

4 months ago

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment HCW Biologics (NASDAQ: HCWB) announced its Chief Scientific Officer, Peter Rhode, PhD, participated in a Virtual Investor “What This Means” segment highlighting the company’s lead candidate HCW11-040, a pembrolizumab-based, tetra-specific fusion protein built on the TRBC platform.HCW11-040 combines pembrolizumab with interleukin-7, interleukin-15, and TGF-β receptor components (TGF-β traps). Preclinical testing reportedly shows expansion of exhausted T cells (TPEX) without causing side effects. Detailed preclinical data will be presented in a poster at SITC on November 8, 2025.

#HCWB HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

5 months ago

Breakthrough in Solid Tumor Treatment: HCW Biologics' Next-Gen T-Cell Platform Shows Superior Safety Profile Biotech firm HCW Biologics advances second-generation T-Cell Engager program with improved manufacturability and safety profile for solid tumor treatment. Study shows positive preclinical results.

#HCWB HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

5 months ago

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing HCW Biologics (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, announced that Wugen, a company in which it holds a minority stake, has secured a $115 million equity financing led by Fidelity Management & Research Company. The financing included participation from several prominent life sciences investors.HCW Biologics' stake in Wugen originated from a 2020 Exclusive License Agreement, which has generated $16.2 million in revenues for HCW through license fees (paid in cash and Wugen stock) and clinical material sales. The funding will support Wugen's development of allogeneic, off-the-shelf CAR-T cell therapies.

#HCWB HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

5 months ago

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid tumors Discovery of unique combination of cytokines in multi-functional fusion protein molecule that exhibits ability to expand TPEX cells without cytokine

#HCWB HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

6 months ago

HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated at a level significantly higher than the identified efficacious dose level Program has addressed key challenges for first generation T-cell engagers related

#HCWB HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program

www.stocktitan.net/news/HCWB/hcw-biologics-...

Small Cap Strategist

@smcapstrategist.bsky.social

6 months ago

Most searched small-cap stocks, Mon Aug 25th - #STSS #CGTX #CIFR #ATAI #VRNT #ETHZ #HIVE #ONDS #BBAI #RR #HCWB #ASST #THM #THAR #MGNI #LIDR #INHD #CBRL #ASM #AEHR - More: crystalequityresearch.com/most-searche... - #smallcap

StockTitan

@stocktitan.net

6 months ago

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid tumors Presentation at Nova Southeastern University on September 12, 2025, in Fort

#HCWB HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

6 months ago

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results HCW Biologics (NASDAQ: HCWB) reported Q2 2025 financial results and business updates. The company completed a $5.0 million equity offering with an institutional investor and extinguished $7.7 million in debt. Key developments include WY Biotech's acceptance of their technical report with a $7.0 million license fee due by September 30, 2025, and a one-year suspension of the Wugen License Agreement to seek alternative licensing for HCW9206.Financial results showed Q2 2025 revenues of $6,550, down from $618,854 in Q2 2024. R&D expenses decreased 40% to $1.2 million, while G&A expenses increased 31% to $2.1 million. Net loss improved to $1.9 million from $15.3 million in Q2 2024. The company regained compliance with Nasdaq listing requirements but noted substantial going concern doubts without additional funding. [ "Successful completion of $5.0 million equity offering", "Extinguishment of $7.7 million in debt through restructuring or conversion", "Regained compliance with all Nasdaq listing requirements", "40% reduction in R&D expenses to $1.2 million", "Net loss improved significantly to $1.9 million from $15.3 million YoY", "Potential $7.0 million license fee from WY Biotech due by September 2025" ]

#HCWB HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

www.stocktitan.net/news/HCWB/hcw-biologics-...

Özgür Trader

@traderozo.bsky.social

8 months ago

#hcwb G #nasdaq #nyse
Güçlü Spek+Piramit

StockTitan

@stocktitan.net

8 months ago

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors HCW Biologics (NASDAQ: HCWB) announced successful development of second-generation, multi-specific T-cell engagers targeting solid tumors, particularly pancreatic cancer, using their proprietary TRBC platform technology. The company's lead T-cell engagers target tissue factor and mesothelin, demonstrating potent anti-pancreatic cancer activities in preclinical studies.The breakthrough technology not only targets cancer antigens and activates T cells but also reduces immunosuppression in the tumor microenvironment. In preclinical studies, 100% survival was observed in tumor-bearing mice treated with TRBC-based T-cell engagers, while untreated mice did not survive. Dr. Hing C. Wong, Founder and CEO, will present these IND-enabling study results at the Phoenix Best Science Series on June 27, 2025.

#HCWB HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

9 months ago

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech HCW Biologics (NASDAQ: HCWB) has successfully completed a technology transfer with WY Biotech, solidifying their license agreement for HCW11-006, a novel immunotherapy molecule. The deal includes a $7.0 million upfront payment to be recognized in Q2 2025, plus potential milestone payments and double-digit royalties on future sales. HCWB retains a cost-free option to reclaim development rights for the Americas after Phase 1 trials. WY Biotech will bear all development and commercialization costs outside the opt-in territory. HCW11-006, developed on HCWB's TRBC platform, has shown promising preclinical results in solid tumor models, effectively stimulating anti-tumor immune responses without significant side effects.

#HCWB HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

9 months ago

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and

#HCWB HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

www.stocktitan.net/news/HCWB/hcw-biologics-...

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

Most searched small-cap stocks, Tue May 13th - #RUN #LICN #HCWB #MLGO #VLRS #UUUU #UEC #TRM #SSYS #SMR #HTZ #RAMP #QBTS #PTEN #MVST #IAS #HL #CAPR #ALLO #ABR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

10 months ago

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules HCW Biologics (NASDAQ: HCWB) has announced the pricing of a $5.0 million follow-on offering at $7.45 per unit. Each unit includes one share of common stock (or pre-funded warrant) and two warrants to purchase common stock. The warrants have an exercise price of $7.45 per share, are immediately exercisable, and expire in five years.The offering is expected to close around May 15, 2025, with Maxim Group LLC acting as sole placement agent. The company plans to use the proceeds for preclinical and clinical development of HCW9302, business development, patent portfolio expansion, and general corporate purposes. Additionally, HCWB has agreed to reduce the exercise price of certain existing warrants from $41.20 to $7.45 per share.

#HCWB HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

www.stocktitan.net/news/HCWB/hcw-biologics-...

Market Wire News

@marketwirenews.com

10 months ago

Breaking News: ( NASDAQ: #HCWB ) HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

StockTitan

@stocktitan.net

10 months ago

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization HCW Biologics (NASDAQ: HCWB) has announced positive results for its proprietary fusion protein HCW9206, demonstrating superior performance in generating CAR-T cells for immunotherapy. The compound shows significant advantages over standard methods using anti-CD3/anti-CD28 and IL-2 reagents for CAR lentiviral transduction.Research presented at the 2025 Annual Meeting of American Association of Immunologists revealed that HCW9206 effectively expands stem cell-like memory T cells (Tscm) carrying CAR constructs, which exhibit better persistence and targeted cell killing. In experimental humanized mouse models, HCW9206-generated CAR-Ts showed enhanced potency in suppressing HIV-1 and leukemic cells compared to standard methods.The company has completed the GMP master cell bank and manufacturing process for HCW9206, with its drug master file submitted to the FDA. HCWB is now seeking commercial partnerships for reagent sales and integration into CAR-T manufacturing processes.

#HCWB HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

www.stocktitan.net/news/HCWB/hcw-biologics-...

Market Wire News

@marketwirenews.com

11 months ago

JUST IN: ( NASDAQ: #HCWB ) HCWB announced stock split 1-40

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

Small-cap stocks with strong volume gains, Wed Apr 2nd - #SONM #TIVC #IBG #VMAR #TCRT #SASR #RPAY #MBIO #HCWB #GLSI #CGNT #ANGO #VLN #FMBS #CLBR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

11 months ago

Major Stock Restructuring: HCW Biologics Announces 40:1 Reverse Split for Nasdaq Compliance Strategic 1-for-40 share consolidation aims to maintain Nasdaq listing. Outstanding shares to reduce to 1.1M while preserving ownership percentages. Full details inside.

#HCWB HCW Biologics Announces 1-for-40 Reverse Stock Split

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

11 months ago

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results HCW Biologics (NASDAQ: HCWB) reported its Q4 and fiscal year 2024 results, highlighting significant developments in its immunotherapy pipeline. The company received FDA clearance to begin Phase 1 trials for HCW9302 in alopecia areata treatment. A notable licensing agreement with WY Biotech is expected to bring in $7.0 million in June 2025.Financial highlights include raising $16.3 million in 2024 through various transactions. However, revenues decreased from $1.3 million in Q4 2023 to $394,000 in Q4 2024. The company's net loss increased from $25.0 million in 2023 to $30.0 million in 2024, largely due to legal expenses.The company faces Nasdaq compliance challenges and must meet listing requirements by April-June 2025. Management acknowledges substantial doubt about continuing operations without additional funding, though financing activities are underway with Maxim Group as Placement Agent.

#HCWB HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

www.stocktitan.net/news/HCWB/hcw-biologics-...

StockTitan

@stocktitan.net

1 year ago

Can HCW Biologics Meet Nasdaq's New June Deadline? Key Details Revealed Nasdaq grants HCWB until June 15 to meet minimum bid price and market value requirements. Company must demonstrate compliance across multiple metrics.

#HCWB HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

www.stocktitan.net/news/HCWB/hcw-biologics-...